A biotech developing antibody drugs for Parkinson's, Alzheimer's, and amyloidosis, aiming to stop misfolded proteins from killing brain and nerve cells.
No product sales; revenue comes from milestone payments under partnerships with Roche and Bristol Myers Squibb, totaling USD 0.14B in 2024. Gross margins are high, but net margins are deeply negative (-80.67% TTM) as R&D burns cash.
Patents and proprietary protein-misfolding expertise create barriers, but Roche and Bristol Myers Squibb hold commercialization rights, diluting Prothena's control. Moat is eroding as larger rivals like Biogen and Eli Lilly advance competing Alzheimer's and Pa
None yet
None yet
Prothena is a clinical biotechnology company developing novel therapies. The post links to an SEC filing, suggesting a regulatory or corporate event is being discussed.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
